Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CLOROX CO /DE/CLX · Entity 3474 | EVP - Chief Financial Officer | September 12, 2017 | September 14, 2017 |
| TrueBlue, Inc.TBI · Entity 5919 | Director | February 07, 2020 | February 11, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CLOROX CO /DE/
Report date September 12, 2017 · Filed September 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $135.57 · Expires 2027-09-12 | Direct | 49,130 |
Reported balance
After 2017-09-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-09-12 · Grant · Acquired 49,130 · Balance 49,130 F1: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date.
TrueBlue, Inc.
Report date February 07, 2020 · Filed February 11, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Deferred Stock AwardSEC Table II · derivative / convertible security | Direct | 39,920 |
Reported balance
After 2020-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-07 · Grant · Acquired 9,626 · Balance 39,920 F1: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock. F2: The deferred stock will 100% vest on the first day of the Issuer's fourth quarter in the current fiscal year. Delivery of the shares to the Reporting Person will be made ninety (90) days after the first anniversary date of his separation from service on the Board of Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock.
F2: The deferred stock will 100% vest on the first day of the Issuer's fourth quarter in the current fiscal year. Delivery of the shares to the Reporting Person will be made ninety (90) days after the first anniversary date of his separation from service on the Board of Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 07, 2020 Filed Feb 11, 2020 23:53 UTC | TrueBlue, Inc. TBI · Entity 5919 | GrantDeferred Stock Award · Derivative | 9,626 | $0.00 | $0.00 |
DisclosureSEC source: 0000768899-20-000023 · wf-form4_158146518482014.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,920 Underlying: Common Stock · 9,626 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock. F2 · derivative.exercise_date: The deferred stock will 100% vest on the first day of the Issuer's fourth quarter in the current fiscal year. Delivery of the shares to the Reporting Person will be made ninety (90) days after the first anniversary date of his separation from service on the Board of Directors. F2 · derivative.expiration_date: The deferred stock will 100% vest on the first day of the Issuer's fourth quarter in the current fiscal year. Delivery of the shares to the Reporting Person will be made ninety (90) days after the first anniversary date of his separation from service on the Board of Directors. Read SEC document |
| February 11, 2019 Filed Feb 14, 2019 00:39 UTC | TrueBlue, Inc. TBI · Entity 5919 | GrantDeferred Stock Award · Derivative | 9,383 | $0.00 | $0.00 |
DisclosureSEC source: 0000768899-19-000059 · wf-form4_155010478110614.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,294 Underlying: Common Stock · 9,383 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock. F2 · derivative.exercise_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) anniversary date of separation from service on the Board of Directors. F2 · derivative.expiration_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) anniversary date of separation from service on the Board of Directors. Read SEC document |
| February 09, 2018 Filed Feb 14, 2018 00:53 UTC | TrueBlue, Inc. TBI · Entity 5919 | GrantDeferred Stock Award · Derivative | 8,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009791 · doc4.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,911 Underlying: Common Stock · 8,005 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock. F2 · derivative.exercise_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) Anniversary date of separation from service on the Board of Directors. F2 · derivative.expiration_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) Anniversary date of separation from service on the Board of Directors. Read SEC document |
| September 12, 2017 Filed Sep 14, 2017 21:26 UTC | CLOROX CO /DE/ CLX · Entity 3474 | GrantStock Option (Right to Buy) · Derivative | 49,130 | $0.00 Strike: $135.57 | $0.00 |
DisclosureSEC source: 0001225208-17-015017 · doc4.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · EVP - Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,130 Underlying: Common Stock · 49,130 shares Expires 2027-09-12 F1 · kind: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date. F1 · derivative.exercise_date: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 22:06 UTC | CLOROX CO /DE/ CLX · Entity 3474 | Tax withholdingCommon Stock | 3,726 | $137.17 | $511,095.42 |
DisclosureSEC source: 0001225208-17-014210 · doc4.xml · nonDerivative · entry 2 Robb Stephen · CIK 0001304159 · EVP - Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,460 F2 · kind: Withholding of stock to pay tax liability under the Company's Stock Withholding Arrangement. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 22:06 UTC | CLOROX CO /DE/ CLX · Entity 3474 | GrantCommon Stock | 9,180 | $137.17 | $1,259,220.60 |
DisclosureSEC source: 0001225208-17-014210 · doc4.xml · nonDerivative · entry 1 Robb Stephen · CIK 0001304159 · EVP - Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,186 F1 · kind: Settlement of 2014 Performance Unit Grant that vested 8/17/2017. Read SEC document |
| February 10, 2017 Filed Feb 15, 2017 00:22 UTC | TrueBlue, Inc. TBI · Entity 5919 | GrantDeferred Stock Award · Derivative | 8,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-010847 · doc4.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,906 Underlying: Common Stock · 8,532 shares Expires not disclosed F1 · derivative.exercise_price: Each deferred stock award represents a right to receive one share of TrueBlue, Inc. common stock. F2 · derivative.exercise_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) Anniversary date of separation from service on the Board of Directors. F2 · derivative.expiration_date: The deferred stock is fully vested. Delivery of the shares to Mr. Robb will be made ninety (90) days after the first (1st) Anniversary date of separation from service on the Board of Directors. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 21:00 UTC | CLOROX CO /DE/ CLX · Entity 3474 | GrantStock Option (Right to Buy) · Derivative | 50,950 | $0.00 Strike: $123.09 | $0.00 |
DisclosureSEC source: 0001225208-16-039405 · doc4.xml · derivative · entry 1 Robb Stephen · CIK 0001304159 · EVP - Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,950 Underlying: Common Stock · 50,950 shares Expires 2026-09-13 F1 · kind: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date. F1 · derivative.exercise_date: Option vests in 4 equal installments - 1/4 on each of the first, second, third and fourth anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.